ATE418333T1 - Kombination aus docetaxel und einem cdk-hemmer - Google Patents

Kombination aus docetaxel und einem cdk-hemmer

Info

Publication number: ATE418333T1
Authority: AT; Austria
Prior art keywords: docetaxel; cdk inhibitor; combination; prodrug; derivative
Prior art date: 2002-11-06

Application number

AT03810527T

Other languages

English (en)

Inventor

Athos Giannella-Borradori

Original Assignee

Cyclacel Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-06

Filing date

2003-11-05

Publication date

2009-01-15

2002-11-06 Priority claimed from GBGB0225872.1A external-priority patent/GB0225872D0/en

2003-08-11 Priority claimed from GB0318813A external-priority patent/GB0318813D0/en

2003-11-05 Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE418333T1 publication Critical patent/ATE418333T1/de

Links

ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title abstract 4
239000002875 cyclin dependent kinase inhibitor Substances 0.000 title abstract 4
229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title abstract 4
229960003668 docetaxel Drugs 0.000 title abstract 4
239000000651 prodrug Substances 0.000 abstract 3
229940002612 prodrug Drugs 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
229940127557 pharmaceutical product Drugs 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

AT03810527T 2002-11-06 2003-11-05 Kombination aus docetaxel und einem cdk-hemmer ATE418333T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0225872.1A GB0225872D0 (en)	2002-11-06	2002-11-06	Combination
GB0318813A GB0318813D0 (en)	2003-08-11	2003-08-11	Combination

Publications (1)

Publication Number	Publication Date
ATE418333T1 true ATE418333T1 (de)	2009-01-15

Family

ID=32313983

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03810527T ATE418333T1 (de)	2002-11-06	2003-11-05	Kombination aus docetaxel und einem cdk-hemmer

Country Status (11)

Country	Link
US (1)	US20050277656A1 (de)
EP (1)	EP1558242B1 (de)
JP (1)	JP4764165B2 (de)
AT (1)	ATE418333T1 (de)
AU (1)	AU2003276467A1 (de)
BR (1)	BR0316010A (de)
CA (1)	CA2502973A1 (de)
DE (1)	DE60325502D1 (de)
ES (1)	ES2318202T3 (de)
MX (1)	MXPA05004917A (de)
WO (1)	WO2004041268A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0012528D0 (en) *	2000-05-23	2000-07-12	Univ Palackeho	Triterpenoid derivatives
WO2005044275A1 (en) *	2003-11-06	2005-05-19	Cyclacel Limited	Use
BRPI0707580A2 (pt) *	2006-02-10	2011-05-10	Nerviano Medical Sciences Srl	combinaÇÕes compreendendo um inibidor cdk e um anticorpo do fator de crescimento ou antimitàtico
DK2596801T3 (en) *	2006-10-06	2018-08-13	Bavarian Nordic As	RECOMBINANT MODIFIED VACCINIA ANKARA VIRUS CODING A HER-2 ANTIGEN FOR USING CANCER TREATMENT
WO2009006555A2 (en) *	2007-07-02	2009-01-08	Yu, Ming	Methods, composition, targets for combinational cancer treatments
JP6286421B2 (ja)	2012-05-15	2018-02-28	サイクラセルリミテッド	サパシタビン及びセリシクリブの投与レジメン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2741881B1 (fr) *	1995-12-01	1999-07-30	Centre Nat Rech Scient	Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6235776B1 (en) *	1998-11-12	2001-05-22	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
GB9904932D0 (en) *	1999-03-04	1999-04-28	Glaxo Group Ltd	Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
WO2002046182A1 (en) *	2000-12-08	2002-06-13	Bristol-Myers Squibb Pharma Company	Semicarbazides and their uses as cyclin dependent kinase inhibitors
US20020182204A1 (en) *	2001-03-23	2002-12-05	Marie-Christine Bissery	Combination of a taxane and a cyclin-dependent kinase
WO2003039536A1 (en) *	2001-11-07	2003-05-15	Yale University	Enhancement of taxane-based chemotherapy by a cdk1 antagonist
JP2005526086A (ja) *	2002-03-15	2005-09-02	サイクラセル・リミテッド	癌の治療用のｃｄｋ阻害剤と５−ｆｕの組合せ
GB0225873D0 (en) *	2002-11-06	2002-12-11	Cyclacel Ltd	Combination
AU2003276463A1 (en) *	2002-11-06	2004-06-07	Cyclacel Limited	Combination comprising a cdk inhibitor and cisplatin
JP2006508184A (ja) *	2002-11-06	2006-03-09	サイクラセル・リミテッド	Ｃｄｋ阻害剤及びゲムシタビンを含む医薬組成物

2003
- 2003-11-05 AT AT03810527T patent/ATE418333T1/de not_active IP Right Cessation
- 2003-11-05 AU AU2003276467A patent/AU2003276467A1/en not_active Abandoned
- 2003-11-05 WO PCT/GB2003/004780 patent/WO2004041268A1/en not_active Ceased
- 2003-11-05 JP JP2005502134A patent/JP4764165B2/ja not_active Expired - Fee Related
- 2003-11-05 BR BR0316010-6A patent/BR0316010A/pt not_active Application Discontinuation
- 2003-11-05 EP EP03810527A patent/EP1558242B1/de not_active Expired - Lifetime
- 2003-11-05 ES ES03810527T patent/ES2318202T3/es not_active Expired - Lifetime
- 2003-11-05 DE DE60325502T patent/DE60325502D1/de not_active Expired - Lifetime
- 2003-11-05 MX MXPA05004917A patent/MXPA05004917A/es unknown
- 2003-11-05 CA CA002502973A patent/CA2502973A1/en not_active Abandoned
2005
- 2005-05-03 US US11/122,331 patent/US20050277656A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ES2318202T3 (es)	2009-05-01
EP1558242B1 (de)	2008-12-24
JP4764165B2 (ja)	2011-08-31
DE60325502D1 (de)	2009-02-05
JP2006508186A (ja)	2006-03-09
EP1558242A1 (de)	2005-08-03
CA2502973A1 (en)	2004-05-21
MXPA05004917A (es)	2005-08-18
BR0316010A (pt)	2005-09-13
WO2004041268A1 (en)	2004-05-21
AU2003276467A1 (en)	2004-06-07
US20050277656A1 (en)	2005-12-15

Similar Documents

Publication	Publication Date	Title
MXPA05004919A (es)	2005-08-18	Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina.
DE602004031462D1 (de)	2011-03-31	Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
EA200501849A1 (ru)	2006-06-30	Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
CY1111263T1 (el)	2015-08-05	Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης
WO2005058233A3 (en)	2005-12-29	Methods for treatment of acute pancreatitis
WO2004045593A3 (en)	2004-08-12	Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
MX2009006327A (es)	2009-06-23	Compuestos heterociclicos y metodos de uso de los mismos.
ATE396986T1 (de)	2008-06-15	Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
IL175568A (en)	2016-05-31	Tyrosine kinase inhibitors, containing them containing herbal remedies and their use in the preparation of a drug for the treatment of diseases
IS6558A (is)	2002-09-20	Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
ATE504303T1 (de)	2011-04-15	Kombination aus roscovitine und cs-682 oder seinem metaboliten cndac
BR0307629A (pt)	2005-01-11	Métodos e composições para tratar condições hiperproliferativas
EA200602047A1 (ru)	2007-06-29	Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
WO2007035963A3 (en)	2007-11-22	Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
ATE523200T1 (de)	2011-09-15	Kombination mit sapacitibin (2'-cyano-2'-desoxy- n4-palmitoyl-1-beta-d-arabinofuranosyl-cytosin) und einem zytotoxischen mittel
ATE353650T1 (de)	2007-03-15	Kombinationstherapie zur behandlung von krebs
EA200601288A1 (ru)	2006-12-29	Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
ATE418333T1 (de)	2009-01-15	Kombination aus docetaxel und einem cdk-hemmer
MXPA05004920A (es)	2005-08-18	Combinacion que comprende un inhibidor cdk y cisplatin.
MXPA04009012A (es)	2004-12-07	Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.
BRPI0511475A (pt)	2007-12-26	combinação, composição farmacêutica, uso de uma combinação, e, método para o tratamento de cáncer
MX2007006557A (es)	2007-06-15	Metodos para utilizar intratecalmente una formulacion de temozolomida en el tratamiento de canceres.
BR0316029A (pt)	2005-09-13	Combinação
MXPA04009396A (es)	2005-01-25	Combinacion que comprende un inhibidor cdk y doxorubicina.
ATE496899T1 (de)	2011-02-15	Tetrahydro- und dihydrochinazolinone

Legal Events

Date

Code

Title

Description

2009-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1558242

Country of ref document: EP

2011-02-15

REN

Ceased due to non-payment of the annual fee